Tag: TEVA

Teva and Celltrion Announced Availability of TRUXIMA® in the U.S.

celltrion
Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd., Celltrion, Inc., and Celltrion Healthcare, Co., Ltd. announced that TRUXIMA® (rituximab-abbs) injection is the ...

Teva Pharmaceutical Announced Settlement Agreement with Ohio Counties

teva
Teva Pharmaceutical Industries Ltd. and its affiliates announced a settlement agreement with both Cuyahoga and Summit counties of Ohio. The settlement resolves the counties’ claims and removes Teva f...

Teva UK Recall Unexpired Stock of Ranitidine Effervescent Tablets

teva
Teva UK Limited trading as ratiopharm GmbH is recalling all unexpired stock of Ranitidine Effervescent Tablets from pharmacies. Product information PL number Ranitidine Effervescent Tablets 150mg P...

Johnson & Johnson and Teva Ready to Pay to Settle Opioid Litigations

Johnson & Johnson has offered to pay $4 billion to settle all claims accusing the company of helping fuel the U.S. opioid epidemic, as part of a potentially larger deal involving drugmakers and di...

Teva and FSUE “Moscow Endocrine Plant” to Introduce Trizenox on Russian Market

On September 16, 2019, as part of the IV annual BIOTECHMED Biotechnology Forum, Teva and FSUE “Moscow Endocrine Plant” signed a Memorandum of Intent to implement actions aimed at introducing the Trize...

Teva Reported 2Q 2019 Financial Results

Teva Pharmaceutical Industries Ltd. reported results for the quarter ended June 30, 2019. Mr. Kåre Schultz, Teva’s President and CEO, said, “During the second quarter, portfolio optimization and n...

FDA Approved Multiple Applications for First Generics of Lyrica

On July 19, the U.S. Food and Drug Administration approved multiple applications for first generics of Lyrica (pregabalin) for the management of neuropathic pain associated with diabetic peripheral ne...

Teva Established North America R&D Campus

Teva Pharmaceuticals USA, Inc. announced that the company has completed the purchase of three buildings on Brandywine Parkway in West Chester, Pa., which, together with three other buildings Teva owns...

NCDA Partners with Teva

NCDA to announce the launch of a new partnership with Teva to foster dialogue around the specific challenges raised by multiple chronic conditions (MCC) in the context of Universal Health Coverage (UH...

Teva’s 1% Sodium Hyaluronate Launched in the U.S.

teva
Teva Pharmaceutical Industries Ltd. announced the launch of 1% Sodium Hyaluronate. The product received approval from the Center for Devices and Radiological Health of the U.S. Food and Drug Administr...

Teva Launch Generic Version of Tracleer in the U.S.

generics
Teva Pharmaceutical Industries Ltd., announced the launch of a generic version of Tracleer® (bosentan) tablets, 62.5 mg and 125 mg, in the U.S. Bosentan Tablets are an endothelin receptor antagonis...

Teva Announced the Launch of Generic Version of Ranexa® in the U.S.

Teva Pharmaceutical Industries Ltd. announced the launch of a generic version of Ranexa® (ranolazine) Extended-Release Tablets, 500 mg and 1000 mg, in the U.S. Ranolazine Extended-Release Tablets a...

Teva Pharmaceutical Agreed to Pay an $85 million to Settle Opioid Claims

teva
Teva Pharmaceutical Industries Ltd said on Sunday it had agreed to pay an $85 million settlement with the state of Oklahoma days before the company was set to face trial over allegations that it and o...

Teva abandons Clinical Development of Fremanezumab Cluster Headache

clinical-trial
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) provided an update that the Company is discontinuing the clinical development program for use of fremanezumab in cluster headaches. A pre-spec...

Teva Paid its New CEO in His First Full Year at the Helm $33M

If you thought Teva had gone big-time with its 2017 pay package for CEO Kåre Schultz, check out what it paid him in 2018. The Israeli drugmaker forked over (PDF) a whopping $32.5 million to...

Teva’s Migraine Drug Got CHMP Positive Opinion

Teva’s migraine drug Ajovy (fremanezumab) has moved closer to the EU market after the influential CHMP regulatory committee gave it the green light. The decision paves the way for European approval...